|
|
 |
 |
| |
 Printable version |
Hormone receptors and HER-2 changes during breast cancer progression: clinical implications |
Bulletin du Cancer. Volume 98, Number 9, 1059-70, Septembre 2011, Synthèse
|
 Résumé
Article gratuit
|
Author(s) : William Jacot, Stéphane Pouderoux, Frédéric Bibeau, Cristina Leaha, Marie-Christine Chateau, Angélique Chapelle, Gilles Romieu |
Summary : Breast cancer remains a major public health problem. Even if there is an increase in this cancer curability, metastatic breast cancer remains a lethal disease in the vast majority of cases. Therapeutic advances in the chemotherapeutic and targeted therapies fields induced an increase in survival, however the proportion of long survivors remains low. Phenotypic instability, an early process initiated during tumour progression, and continued on the metastatic stage of the disease, can be one of the putative hypotheses explaining these results. An increasing amount of scientific data are pledging for a reanalysis of the phenotypic profile regarding hormone receptors and HER-2 status of metastatic lesions in order to identify drugable targets and allow individualisation of the treatment of these metastatic breast cancer patients. Phenotypic changes between the primary tumour and the paired metastatic lymph nodes are a challenging pitfall, raising the question of which site has to be assessed in the adjuvant treatment decision process. This article presents a comprehensive analysis of the frequency of theses phenotypic changes altogether with new modalities to evaluate this phenotypic status. |
Keywords : breast cancer, metastases, phenotypic changes, targeted therapies |
|
